{"DataElement":{"publicId":"5335516","version":"1","preferredName":"Intended route of administration","preferredDefinition":"Determination of the intended route of administration.","longName":"5332755v1.0:5335396v1.0","context":"AHRQ","contextVersion":"1","DataElementConcept":{"publicId":"5332755","version":"1","preferredName":"Intended route of administration","preferredDefinition":"No Value Exists","longName":"5332753v1.0","context":"ONC SDC Project","contextVersion":"1","ObjectClass":{"publicId":"5332753","version":"1","preferredName":"Intended route of administration:Find:Pt:^Patient:Nom:AHRQ","preferredDefinition":"No Value Exists","longName":"74051-4","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intended route of administration:Find:Pt:^Patient:Nom:AHRQ","conceptCode":"74051-4","definition":"No Value Exists","evsSource":"LOINC_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3672CE43-E4AE-E1F7-E050-BB89AD432B03","latestVersionIndicator":"Yes","beginDate":"2016-06-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-06-29","modifiedBy":"ONEDATA","dateModified":"2016-06-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7318108","version":"1","preferredName":"Unspecified Property","preferredDefinition":"Not stated explicitly or in detail.:A basic or essential attribute shared by all members of a class.","longName":"C38046:C42605","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unspecified","conceptCode":"C38046","definition":"Not stated explicitly or in detail.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Property","conceptCode":"C42605","definition":"A basic or essential attribute shared by all members of a class.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A71D5FBC-8406-6D97-E053-4EBD850AE7DA","latestVersionIndicator":"Yes","beginDate":"2020-06-02","endDate":null,"createdBy":"DWARZEL","dateCreated":"2020-06-02","modifiedBy":"ONEDATA","dateModified":"2020-06-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AHRQ:AHRQ Common Formats","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3672CE43-E4BB-E1F7-E050-BB89AD432B03","latestVersionIndicator":"Yes","beginDate":"2016-06-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-06-29","modifiedBy":"REEVESD","dateModified":"2017-02-10","changeDescription":"Created to support registration of AHRQ Common Formats CDEs 2016/2017.dmr","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5335396","version":"1","preferredName":"Intended route of administration Type","preferredDefinition":"Something distinguishable as an identifiable class based on common qualities.","longName":"5335396v1.0","context":"ONC SDC Project","contextVersion":"1","type":"Enumerated","dataType":"HL7CDv3","minLength":"3","maxLength":"5","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"A1440","valueDescription":"Cutaneous Route of Administration","ValueMeaning":{"publicId":"5349751","version":"1","preferredName":"Cutaneous Route of Administration","longName":"5349751","preferredDefinition":"Administration to the skin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cutaneous Route of Administration","conceptCode":"C38675","definition":"Administration to the skin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"37B60D39-1F60-77DC-E050-BB89AD43670B","latestVersionIndicator":"Yes","beginDate":"2016-07-15","endDate":null,"createdBy":"DWARZEL","dateCreated":"2016-07-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"392FB435-7BD7-E7A3-E050-BB89AD430D98","beginDate":"2016-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-08-03","modifiedBy":"ONEDATA","dateModified":"2016-08-03","deletedIndicator":"No"},{"value":"A1443","valueDescription":"Subcutaneous Route of Administration","ValueMeaning":{"publicId":"5335421","version":"1","preferredName":"Subcutaneous Route of Administration","longName":"5335421","preferredDefinition":"Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Subcutaneous Route of Administration","conceptCode":"C38299","definition":"Drug administration beneath the skin. It provides for relatively slow, sustained release of the drug. The rate of absorption into the blood is perfusion-limited, proportional to the amount of drug at the site and can be enhanced by chemical or physical stimulation of blood flow. Subcutaneous administration minimizes the risks associated with intravascular injection: for subcutaneous infusions, external and implantable pumps are used.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"36E51D41-A0D2-74F7-E050-BB89AD4334C4","latestVersionIndicator":"Yes","beginDate":"2016-07-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"392FB435-7BEB-E7A3-E050-BB89AD430D98","beginDate":"2016-07-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-08-03","modifiedBy":"ONEDATA","dateModified":"2016-08-03","deletedIndicator":"No"},{"value":"A1444","valueDescription":"Ophthalmic Route of Administration","ValueMeaning":{"publicId":"5335419","version":"1","preferredName":"Ophthalmic Route of Administration","longName":"5335419","preferredDefinition":"Administration of a drug to the external eye.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ophthalmic Route of Administration","conceptCode":"C38287","definition":"Administration of a drug to the external surfaces of the eye.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"36E51D41-A0AC-74F7-E050-BB89AD4334C4","latestVersionIndicator":"Yes","beginDate":"2016-07-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"392FB435-7BFF-E7A3-E050-BB89AD430D98","beginDate":"2016-07-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-08-03","modifiedBy":"ONEDATA","dateModified":"2016-08-03","deletedIndicator":"No"},{"value":"A1446","valueDescription":"Oral, including sublingual or buccal Oral Route of Administration","ValueMeaning":{"publicId":"5335417","version":"1","preferredName":"Oral, including sublingual or buccal Oral Route of Administration","longName":"5335417","preferredDefinition":"The introduction of a substance to the mouth or into the gastrointestinal tract by the way of the mouth, usually for systemic action. It is the most common, convenient, and usually the safest and least expensive route of drug administration, but it uses the most complicated pathway to the tissues and bioavailability varies. The disadvantages of method are hepatic first pass metabolism and enzymatic degradation of the drug within the gastrointestinal tract. This prohibits oral administration of certain classes of drugs especially peptides and proteins.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oral Route of Administration","conceptCode":"C38288","definition":"The introduction of a substance to the mouth or into the gastrointestinal tract by the way of the mouth, usually for systemic action. It is the most common, convenient, and usually the safest and least expensive route of drug administration, but it uses the most complicated pathway to the tissues and bioavailability varies. The disadvantages of method are hepatic first pass metabolism and enzymatic degradation of the drug within the gastrointestinal tract. This prohibits oral administration of certain classes of drugs especially peptides and proteins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"36E51D41-A086-74F7-E050-BB89AD4334C4","latestVersionIndicator":"Yes","beginDate":"2016-07-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"392FB435-7C13-E7A3-E050-BB89AD430D98","beginDate":"2016-07-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-08-03","modifiedBy":"ONEDATA","dateModified":"2016-08-03","deletedIndicator":"No"},{"value":"A1447","valueDescription":"Auricular Route of Administration","ValueMeaning":{"publicId":"5335415","version":"1","preferredName":"Auricular Route of Administration","longName":"5335415","preferredDefinition":"Administration to or by way of the ear.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Auricular Route of Administration","conceptCode":"C38192","definition":"Administration of the drug to or by way of the ear. The drug action is mostly topical/local.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"36E51D41-A060-74F7-E050-BB89AD4334C4","latestVersionIndicator":"Yes","beginDate":"2016-07-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"392FB435-7C27-E7A3-E050-BB89AD430D98","beginDate":"2016-07-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-08-03","modifiedBy":"ONEDATA","dateModified":"2016-08-03","deletedIndicator":"No"},{"value":"A1449","valueDescription":"Nasal Route of Administration","ValueMeaning":{"publicId":"5335414","version":"1","preferredName":"Nasal Route of Administration","longName":"5335414","preferredDefinition":"Administration of a drug by the way of the nose. This often results in systemic action of the agent due to absorption through the nasal mucosa. The richly supplied vascular nature of the nasal mucosa coupled with its high drug permeation makes the nasal route of administration attractive for many drugs, including proteins and peptides.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nasal Route of Administration","conceptCode":"C38284","definition":"Administration of a drug by the way of the nose. This often results in systemic action of the agent due to absorption through the nasal mucosa. The richly supplied vascular nature of the nasal mucosa coupled with its high drug permeation makes the nasal route of administration attractive for many drugs, including proteins and peptides.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"36E51D41-A03B-74F7-E050-BB89AD4334C4","latestVersionIndicator":"Yes","beginDate":"2016-07-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"392FB435-7C3B-E7A3-E050-BB89AD430D98","beginDate":"2016-07-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-08-03","modifiedBy":"ONEDATA","dateModified":"2016-08-03","deletedIndicator":"No"},{"value":"A1450","valueDescription":"Inhalation Route of Administration","ValueMeaning":{"publicId":"5335412","version":"1","preferredName":"Inhalation Route of Administration","longName":"5335412","preferredDefinition":"Administration of a substance in the form of a gas, aerosol, or fine powder via the respiratory tract, usually by oral or nasal inhalation, for local or systemic effect.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inhalation Route of Administration","conceptCode":"C38216","definition":"Administration of a substance in the form of a gas, aerosol, or fine powder via the respiratory tract, usually by oral or nasal inhalation, for local or systemic effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"36E51D41-A015-74F7-E050-BB89AD4334C4","latestVersionIndicator":"Yes","beginDate":"2016-07-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"392FB435-7C4F-E7A3-E050-BB89AD430D98","beginDate":"2016-07-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-08-03","modifiedBy":"ONEDATA","dateModified":"2016-08-03","deletedIndicator":"No"},{"value":"A1452","valueDescription":"Intravenous Route of Administration","ValueMeaning":{"publicId":"5335410","version":"1","preferredName":"Intravenous Route of Administration","longName":"5335410","preferredDefinition":"Administration within or into a vein or veins.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intravenous Route of Administration","conceptCode":"C38276","definition":"Administration of a drug within or into a vein or veins. Introduction of the drug directly into venous circulation results in 100% bioavailability due to an absence of the absorption phase, provides a precise and continuous mode of drug therapy, especially for drugs with a narrow therapeutic index.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"36E51D41-9FEF-74F7-E050-BB89AD4334C4","latestVersionIndicator":"Yes","beginDate":"2016-07-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-05","modifiedBy":"KUMMEROA","dateModified":"2022-12-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"392FB435-7C63-E7A3-E050-BB89AD430D98","beginDate":"2016-07-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-08-03","modifiedBy":"ONEDATA","dateModified":"2016-08-03","deletedIndicator":"No"},{"value":"A1455","valueDescription":"Intramuscular Route of Administration","ValueMeaning":{"publicId":"5335408","version":"1","preferredName":"Intramuscular Route of Administration","longName":"5335408","preferredDefinition":"Administration within a muscle.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intramuscular Route of Administration","conceptCode":"C28161","definition":"Intramuscular injection is a route of drug administration via injection into muscle tissue. Aqueous or oleaginous solutions and emulsions or suspensions may be administered. Absorption rates, delay in availability of the drug to the systemic circulation, and duration of effect are perfusion-limited, depend on molecular size of the agent, volume, and osmolarity of the drug solution, fat content of the injection site, and patient physical activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"36E51D41-9FC9-74F7-E050-BB89AD4334C4","latestVersionIndicator":"Yes","beginDate":"2016-07-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"392FB435-7C77-E7A3-E050-BB89AD430D98","beginDate":"2016-07-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-08-03","modifiedBy":"ONEDATA","dateModified":"2016-08-03","deletedIndicator":"No"},{"value":"A1458","valueDescription":"Intrathecal Route of Administration","ValueMeaning":{"publicId":"5335406","version":"1","preferredName":"Intrathecal Route of Administration","longName":"5335406","preferredDefinition":"Administration within the cerebrospinal fluid at any level of the cerebrospinal axis, including injection into the cerebral ventricles.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intrathecal Route of Administration","conceptCode":"C38267","definition":"Administration of drugs directly into spinal subarachnoid space in the cerebrospinal fluid, at any level of the cerebrospinal axis, including injection into the cerebral ventricles, in order to bypass the blood-brain barrier and achieve local, rapid effects on the meninges or cerebrospinal axis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"36E51D41-9FA3-74F7-E050-BB89AD4334C4","latestVersionIndicator":"Yes","beginDate":"2016-07-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"392FB435-7C8B-E7A3-E050-BB89AD430D98","beginDate":"2016-07-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-08-03","modifiedBy":"ONEDATA","dateModified":"2016-08-03","deletedIndicator":"No"},{"value":"A1461","valueDescription":"Epidural Route of Administration","ValueMeaning":{"publicId":"5335404","version":"1","preferredName":"Epidural Route of Administration","longName":"5335404","preferredDefinition":"Administration of the drug in the epidural space, usually at the lumbar level of the spine. The drug must initially cross the dura mater before exerting its effect on the nervous system components. The drug is also subject to uptake into the rich epidural plexus of veins. Uptake and distribution after epidural administration resembles that seen after intramuscular injection. The portion of drug that is not taken into the vascular compartment is available to cross the dura. Hydrophilicity is a major component in the pharmacokinetics of drug transfer into the subdural space.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Epidural Route of Administration","conceptCode":"C38210","definition":"Administration of the drug in the epidural space, usually at the lumbar level of the spine. The drug must initially cross the dura mater before exerting its effect on the nervous system components. The drug is also subject to uptake into the rich epidural plexus of veins. Uptake and distribution after epidural administration resembles that seen after intramuscular injection. The portion of drug that is not taken into the vascular compartment is available to cross the dura. Hydrophilicity is a major component in the pharmacokinetics of drug transfer into the subdural space.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"36E51D41-9F7D-74F7-E050-BB89AD4334C4","latestVersionIndicator":"Yes","beginDate":"2016-07-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"392FB435-7C9F-E7A3-E050-BB89AD430D98","beginDate":"2016-07-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-08-03","modifiedBy":"ONEDATA","dateModified":"2016-08-03","deletedIndicator":"No"},{"value":"A1464","valueDescription":"Gastric","ValueMeaning":{"publicId":"5335402","version":"1","preferredName":"Gastric","longName":"5335402","preferredDefinition":"Relating to the stomach.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gastric","conceptCode":"C13307","definition":"Relating to the stomach.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"36E51D41-9F57-74F7-E050-BB89AD4334C4","latestVersionIndicator":"Yes","beginDate":"2016-07-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"392FB435-7CB3-E7A3-E050-BB89AD430D98","beginDate":"2016-07-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-08-03","modifiedBy":"ONEDATA","dateModified":"2016-08-03","deletedIndicator":"No"},{"value":"A1467","valueDescription":"Rectal","ValueMeaning":{"publicId":"5335400","version":"1","preferredName":"Rectal","longName":"5335400v1.00","preferredDefinition":"The introduction of a substance into the gastrointestinal tract by the way of the rectum, usually for systemic action. Depending on the molecular structure, drugs cross the rectal wall via either intercellular or tight junctions interconnecting the mucosal cells. Drug absorption is usually around 50% of normal oral dose. Due to the drainage pattern of the rectal veins, the hepatic first-pass effect tends to increase as the dosage form is placed deeper into the rectum. Solid suppositories represent greater than 98% of all rectal dosage forms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rectal Route of Administration","conceptCode":"C38295","definition":"The introduction of a substance into the gastrointestinal tract by the way of the rectum, usually for systemic action. Depending on the molecular structure, drugs cross the rectal wall via either intercellular or tight junctions interconnecting the mucosal cells. Drug absorption is usually around 50% of normal oral dose. Due to the drainage pattern of the rectal veins, the hepatic first-pass effect tends to increase as the dosage form is placed deeper into the rectum. Solid suppositories represent greater than 98% of all rectal dosage forms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"36E51D41-9F31-74F7-E050-BB89AD4334C4","latestVersionIndicator":"Yes","beginDate":"2016-07-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-05","modifiedBy":"KUMMEROA","dateModified":"2023-08-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"392FB435-7CC7-E7A3-E050-BB89AD430D98","beginDate":"2016-07-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-08-03","modifiedBy":"ONEDATA","dateModified":"2016-08-03","deletedIndicator":"No"},{"value":"A1470","valueDescription":"Vaginal Route of Administration","ValueMeaning":{"publicId":"5335398","version":"1","preferredName":"Vaginal Route of Administration","longName":"5335398","preferredDefinition":"Administration of a drug into the vagina. The medication usually has the form of a solution, tablet, cream, gel, or suppository. The drug is slowly absorbed through the vaginal wall with predominantly local, but some systemic effects.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vaginal Route of Administration","conceptCode":"C38313","definition":"Administration of a drug into the vagina. The medication usually has the form of a solution, tablet, cream, gel, or suppository. The drug is slowly absorbed through the vaginal wall with predominantly local, but some systemic effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"36E51D41-9F0B-74F7-E050-BB89AD4334C4","latestVersionIndicator":"Yes","beginDate":"2016-07-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"392FB435-7CDB-E7A3-E050-BB89AD430D98","beginDate":"2016-07-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-08-03","modifiedBy":"ONEDATA","dateModified":"2016-08-03","deletedIndicator":"No"},{"value":"UNK","valueDescription":"Unknown","ValueMeaning":{"publicId":"2565695","version":"1","preferredName":"Unknown","longName":"2565695","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-CDAC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-02-26","endDate":null,"createdBy":"MEDVEDOH","dateCreated":"2003-02-26","modifiedBy":"MMADDINENI","dateModified":"2024-02-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"392FB435-7CE5-E7A3-E050-BB89AD430D98","beginDate":"2016-07-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-08-03","modifiedBy":"ONEDATA","dateModified":"2016-08-03","deletedIndicator":"No"},{"value":"A66","valueDescription":"Other: PLEASE SPECIFY","ValueMeaning":{"publicId":"5333812","version":"1","preferredName":"Other: PLEASE SPECIFY","longName":"5333812v1.00","preferredDefinition":"A directive to indicate a response not listed.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Specify Other","conceptCode":"C157106","definition":"A directive to indicate a response not listed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"36834A90-0046-093D-E050-BB89AD4345E4","latestVersionIndicator":"Yes","beginDate":"2016-06-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-06-30","modifiedBy":"KUMMEROA","dateModified":"2023-08-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"392FB435-7CEF-E7A3-E050-BB89AD430D98","beginDate":"2016-07-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-08-03","modifiedBy":"ONEDATA","dateModified":"2016-08-03","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AHRQ:AHRQ Common Formats","workflowStatus":"RELEASED","registrationStatus":"Application","id":"36E51D41-9EC9-74F7-E050-BB89AD4334C4","latestVersionIndicator":"Yes","beginDate":"2016-07-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-05","modifiedBy":"KUMMEROA","dateModified":"2023-08-28","changeDescription":null,"administrativeNotes":"2023.8.28 Updated PV def for 'No Value Exists'. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"4382693","version":"1","longName":"AHRQ Common Formats","context":"AHRQ","ClassificationSchemeItems":[{"publicId":"5406431","version":"1","longName":"MEDICATION 1.2","context":"AHRQ"}]}],"AlternateNames":[{"name":"DE348","type":"AHRQ Identifier","context":"ONC SDC Project"}],"ReferenceDocuments":[{"name":"What was the intended route o","type":"Preferred Question Text","description":"What was the intended route of administration?","url":null,"context":"ONC SDC Project"},{"name":"MEDICATION|74080-3","type":"AHRQ Form","description":"Medication or Other Substance|Patient safety event report - hospital: medication or other substance - version 1.2 [AHRQ]","url":"https://www.psoppc.org/psoppc_web/DLMS/downloadDocument?groupId&#61;100&amp;pageName&#61;common%20formats%20version%201.2%20technical%20specifications","context":"ONC SDC Project"}],"origin":"AHRQ:AHRQ Common Formats","workflowStatus":"RELEASED","registrationStatus":"Application","id":"36E74471-9BF0-B10C-E050-BB89AD436D95","latestVersionIndicator":"Yes","beginDate":"2010-03-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-05","modifiedBy":"DWARZEL","dateModified":"2017-02-28","changeDescription":"Curated as part of AHRQ Common Format CDE creation.1.15.2017.dmr","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}